Uptake of tumour necrosis factor – alpha inhibitor biosimilars for psoriasis: A drug utilisation study from BADBIR
BJD, 2023.
Phan DB, Bewley AP, Smith CH, Mackenzie T, Griffiths CEM, Lunt M, Warren RB, Yiu ZZN; BADBIR Study Group.
Read publication: BJD
Related
Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-b...
The British Association of Dermatologists Biologics and Immunomodulators Register: a centenary celeb...
Age and biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the Br...
0 Comments